1. The danger of following traditions: The trivial case of the missing heritability Max Moldovan Bioinformatics Division, WEHI [email protected] Seminar…

Curing Hepatitis C: Individualized Approach and New Therapies Lorenzo Rossaro, MD Gastroenterology and Hepatology University of California Davis Medical Center c/o  Liver…

Slide 1 Slide 2 HIV and Hepatitis Workshop Kathleen Clanon, MD [email protected] 8/06 Slide 3 Treatment of HCV in Coinfected Patients Slide 4 Why Do We Need to Treat HIV/HCV…

Slide 1 Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline treatment…

Slide 1 1 Advances in the treatment of chronic hepatitis C: Update to the Committee PEG-Intron/RebetolPEG-Intron/Rebetol Slide 2 2 Treating chronic hepatitis C 10 years of…

Slide 1 EASL 2011 31 March 2011 - Berlin, Germany Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in…

Slide 1 Sameh W. Boktor, MD, MPH Medical Epidemiologist Pennsylvania Department of Health Harrisburg, Pennsylvania Slide 2 Off-label and/or investigational use of pharmaceuticals…

Slide 1 1 Design evaluation and optimization for models of hepatitis C viral dynamics Jeremie Guedj 1,2 Caroline Bazzoli 3 Avidan Neumann 2 France Mentré 3 1 Los Alamos…

PowerPoint Presentation Global distribution and prevalence of hepatitis C virus genotypes Hepatology Volume 61, Issue 1, pages 77-87, 28 JUL 2014 DOI: 10.1002/hep.27259 http://onlinelibrary.wiley.com/doi/10.1002/hep.27259/full#hep27259-fig-0001…

OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS “C” A CLINICAL STUDY BY PROF. M. N. MAWSOUF*,**, DR. T. T. TANBOULI **& DR. W. I. EL-TAYAR** * Cancer Institute, Cairo…